| NCT05464784 | MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia | RECRUITING | PHASE2 | 2022-08-22 | 2026-12-31 | 2025-12-31 |
| NCT04429555 | Efficacy, Safety, Tolerability, and Biomarkers of Ibudilast (MN-166) in Patients Hospitalized With COVID-19 at Risk for ARDS | COMPLETED | PHASE2 | 2021-01-11 | 2024-08-07 | 2022-06-30 |
| NCT04057898 | Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | ACTIVE_NOT_RECRUITING | PHASE2, PHASE3 | 2020-05-28 | 2026-12 | 2025-12 |
| NCT04054206 | Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers | COMPLETED | PHASE1 | 2019-06-24 | 2020-05-31 | 2019-07-17 |
| NCT03782415 | Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma | COMPLETED | PHASE1, PHASE2 | 2018-12-29 | 2023-08-07 | 2023-08-07 |
| NCT03533387 | Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers | COMPLETED | PHASE1 | 2018-04-11 | 2018-09-30 | 2018-07-06 |
| NCT02714036 | A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) | COMPLETED | PHASE1, PHASE2 | 2016-05-06 | 2020-06-30 | 2019-12-31 |
| NCT02503657 | Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary Fibrosis | COMPLETED | PHASE2 | 2016-03-09 | 2022-03-15 | 2020-12-07 |
| NCT02681055 | Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects | COMPLETED | PHASE2 | 2016-03 | 2019-10-01 | 2018-05-30 |
| NCT02238626 | Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS) | COMPLETED | PHASE2 | 2014-09 | 2017-12 | 2017-08 |
| NCT01982942 | Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis | COMPLETED | PHASE2 | 2013-11 | 2017-12 | 2017-05 |
| NCT01551316 | Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients | COMPLETED | PHASE1 | 2012-03 | 2012-05 | 2012-05 |
| NCT01013142 | Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | COMPLETED | PHASE1 | 2009-11 | 2010-03 | 2010-03 |
| NCT00838591 | Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma | COMPLETED | PHASE2 | 2009-03 | 2012-03 | 2012-03 |
| NCT00683449 | Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma | TERMINATED | PHASE2 | 2008-06 | 2009-03 | 2009-03 |
| NCT00679263 | Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma | COMPLETED | PHASE2 | 2008-02 | 2008-07 | 2008-07 |
| NCT00295854 | Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis | COMPLETED | PHASE2 | 2005-05 | 2006-10 | 2006-10 |